SCHEMBL345522

SCHEMBL345522

NC(=O)Cn1c(=O)ccc2cccc(Cl)c21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 1/20 0.39
HPGD P15428 1/20 0.37
RAD52 P43351 1/20 0.36
KMT2A Q03164 4/20 0.35
POLB P06746 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
MEN1 O00255 2/20 0.33
LMNA P02545 2/20 0.33
CCR9 P51686 1/20 0.33
XBP1 P17861 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
MAOA P21397 1/20 0.33
ADRA1D P25100 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL346879 0.82 CSNK2A2 (0.38) HPGDRAD52KMT2APOLBMEN1
SCHEMBL2012127 0.75 NPY5R (0.44) CCR2HPGDRAD52KMT2APOLB
SCHEMBL346784 0.71 MAPT (0.35) CCR2POLBLMNACYP3A4CYP2C9
SCHEMBL347208 0.70 MAPT (0.45) CCR2KMT2A
SCHEMBL11286560 0.68 BRPF1 (0.50) HPGDKMT2AMEN1MAPK1
SCHEMBL17477618 0.66 HPGD (0.41) HPGDKMT2APOLBLMNACYP2C19
SCHEMBL4414547 0.66 HPGD (0.60) HPGDPOLBMAPK1
SCHEMBL29143300 0.65 HTR6 (0.44) CCR2KMT2APOLBMEN1LMNA
SCHEMBL5040066 0.65 HTR6 (0.47) CCR2HPGDKMT2APOLBMEN1
SCHEMBL19837233 0.65 HDAC1 (0.41) CCR2HPGDRXFP1LMNAHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015977-A1 QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS NEUROSEARCH A/S (DK) 2012-01-19 US claimed
EP-2387562-A1 Quinolinone derivatives useful for the treatment of cns disorders NeuroSearch A/S (DK) 2011-11-23 EP claimed
WO-2010081900-A1 QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS NEUROSEARCH A/S (DK) 2010-07-22 WO claimed
US-20120015977-A1 QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS NEUROSEARCH A/S (DK) 2012-01-19 US disclosed
EP-2387562-A1 Quinolinone derivatives useful for the treatment of cns disorders NeuroSearch A/S (DK) 2011-11-23 EP disclosed
WO-2010081900-A1 QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS NEUROSEARCH A/S (DK) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015977-A1 QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS AQP4, PMP22, CHRNA2 CCR2 300/4885HPGD 1322/4885RAD52 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.